These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27197305)

  • 41. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
    Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
    Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
    Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
    Willuda J; Linden L; Lerchen HG; Kopitz C; Stelte-Ludwig B; Pena C; Lange C; Golfier S; Kneip C; Carrigan PE; Mclean K; Schuhmacher J; von Ahsen O; Müller J; Dittmer F; Beier R; El Sheikh S; Tebbe J; Leder G; Apeler H; Jautelat R; Ziegelbauer K; Kreft B
    Mol Cancer Ther; 2017 May; 16(5):893-904. PubMed ID: 28292941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
    Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
    Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
    Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
    Nishigaki T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hara H; Sugase T; Otsuru T; Saito Y; Tsujii S; Nomura T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Eguchi H; Yamasaki M; Mori M; Doki Y; Naka T
    Br J Cancer; 2020 Apr; 122(9):1333-1341. PubMed ID: 32152502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
    Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
    J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
    Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
    Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma.
    Yokota K; Serada S; Tsujii S; Toya K; Takahashi T; Matsunaga T; Fujimoto M; Uemura S; Namikawa T; Murakami I; Kobayashi S; Eguchi H; Doki Y; Hanazaki K; Naka T
    Mol Cancer Ther; 2021 Sep; 20(9):1713-1722. PubMed ID: 34224365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.
    Temming K; Meyer DL; Zabinski R; Senter PD; Poelstra K; Molema G; Kok RJ
    Mol Pharm; 2007; 4(5):686-94. PubMed ID: 17683157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
    Pillow TH; Schutten M; Yu SF; Ohri R; Sadowsky J; Poon KA; Solis W; Zhong F; Del Rosario G; Go MAT; Lau J; Yee S; He J; Liu L; Ng C; Xu K; Leipold DD; Kamath AV; Zhang D; Masterson L; Gregson SJ; Howard PW; Fang F; Chen J; Gunzner-Toste J; Kozak KK; Spencer S; Polakis P; Polson AG; Flygare JA; Junutula JR
    Mol Cancer Ther; 2017 May; 16(5):871-878. PubMed ID: 28223423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
    Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
    Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
    Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
    Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
    Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
    Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.